Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

553
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
553
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

631
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
631
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

2.2K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.2K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

406
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
406
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

689
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
689
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

2.7K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and Economic Outcomes Following First-Time Myocardial Infarction: A Nationwide Cohort Study from the SWEDEHEART Registry.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Health care resource utilization and costs of major bleeding in patients with and without dialysis-dependent end-stage kidney disease: a retrospective study.

Research and practice in thrombosis and haemostasis·2026
Same author

Rethinking "Very High-Risk" ASCVD: Most Patients Qualify, Few Are Distinct?

JACC. Advances·2026
Same author

Multinational Real-World Practice Patterns in the Use of Antithrombotic Therapy Among Patients on Hemodialysis and Peritoneal Dialysis.

Kidney medicine·2026
Same author

Optimizing low-density lipoprotein cholesterol (LDL-C) management - a US physician survey of barriers and burdens.

American journal of preventive cardiology·2026
Same author

Characterizing real-world use of vericiguat in the United States.

Journal of cardiac failure·2025

Related Experiment Video

Updated: Oct 13, 2025

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
08:50

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy

Published on: June 25, 2013

13.4K

Neuromuscular Blockade and Reversal Practice Variability in the Outpatient Setting: Insights From US Utilization

Lori D Bash1, Wynona Black2, Vladimir Turzhitsky2

  • 1From the Center for Observational and Real-World Evidence (CORE), Merck & Co, Inc, Kenilworth, New Jersey.

Anesthesia and Analgesia
|November 16, 2021
PubMed
Summary
This summary is machine-generated.

Active neuromuscular blockade (NMB) reversal increased in US outpatient surgery after sugammadex introduction. Practice patterns vary significantly based on patient, procedure, and site factors, indicating an evolving landscape in anesthesia management.

More Related Videos

Author Spotlight: Enhancing Success of Ultrasound-Guided Neuraxial Anesthesia in Cases with Difficult Anatomy
03:14

Author Spotlight: Enhancing Success of Ultrasound-Guided Neuraxial Anesthesia in Cases with Difficult Anatomy

Published on: January 31, 2025

696
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.0K

Related Experiment Videos

Last Updated: Oct 13, 2025

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
08:50

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy

Published on: June 25, 2013

13.4K
Author Spotlight: Enhancing Success of Ultrasound-Guided Neuraxial Anesthesia in Cases with Difficult Anatomy
03:14

Author Spotlight: Enhancing Success of Ultrasound-Guided Neuraxial Anesthesia in Cases with Difficult Anatomy

Published on: January 31, 2025

696
Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.0K

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Health Services Research

Background:

  • Neuromuscular blockade (NMB) is essential in surgery, but data on its management and reversal in US ambulatory settings are limited.
  • Understanding current practice patterns is crucial for optimizing patient care and safety.

Purpose of the Study:

  • To analyze trends in NMB agent (NMBA) use and reversal strategies in US adult outpatients.
  • To identify factors associated with NMB reversal approaches in ambulatory surgery.

Main Methods:

  • Retrospective analysis of the Premier Healthcare Database (January 2014–June 2019).
  • Inclusion of ~5.2 million outpatient encounters involving NMB.
  • Multivariable logistic regression to assess patient, procedural, and site characteristics influencing NMB reversal.

Main Results:

  • Rocuronium/vecuronium use increased post-sugammadex introduction (~2016), while succinylcholine use decreased.
  • Active pharmacological reversal rose, with neostigmine and sugammadex used in 42.3% and 36.0% of encounters by 2019, respectively.
  • Patient comorbidities, procedure type, and time since 2016 influenced reversal method (neostigmine vs. sugammadex vs. spontaneous).

Conclusions:

  • Active pharmacological reversal of NMB increased in US outpatients post-sugammadex, yet practice variability persists.
  • Patient, procedural, and environmental factors significantly impact NMB management, highlighting an evolving anesthesia practice.
  • Further research is needed on ambulatory care shifts, patient outcomes, and health disparities in NMB management.